Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Open-label zonisamide for refractory migraine.

Miles E Drake1, Nancy I Greathouse, Janet B Renner

  • 1Ohio State University, Columbus, Ohio 43210, USA. medrake1@pol.net

Clinical Neuropharmacology
|December 23, 2004
PubMed
Summary

Zonisamide, an anticonvulsant, significantly reduced migraine severity, frequency, and duration in patients with refractory headaches. This open-label study suggests zonisamide is a well-tolerated option for migraine prevention.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Characterization of Propranolol Use and Outcomes in Traumatic Brain Injury at a Level I Trauma Center.

Clinical neuropharmacology·2026
Same journal

Review of Medications That Reduce Neurological Deficits in Patients With Traumatic Brain Injury.

Clinical neuropharmacology·2026
Same journal

Pre-Existing Peak-Dose Dyskinesia and Light Body Weight as Predictors of Ropinirole Patch Dose Modification in Parkinson Disease: A Multicenter Retrospective Study.

Clinical neuropharmacology·2026
Same journal

A Double-blind, Placebo-controlled Study of Lumateperone in the Treatment of Borderline Personality Disorder.

Clinical neuropharmacology·2026
Same journal

Yesterday Once More: Revisiting Catatonia in an Elderly Stroke Patient.

Clinical neuropharmacology·2026
Same journal

Overlapping Hyperosmolar Therapy in Patients With Elevated and Refractory Intracranial Pressure.

Clinical neuropharmacology·2026

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Migraine headaches represent a significant neurological disorder with unmet treatment needs.
  • Zonisamide is a novel anticonvulsant with a multifaceted mechanism of action.
  • Its potential efficacy in migraine treatment warrants investigation, particularly in refractory cases.

Purpose of the Study:

  • To investigate the efficacy and tolerability of open-label zonisamide in patients suffering from refractory migraine headaches.
  • To assess the impact of zonisamide on headache severity, frequency, and duration.

Main Methods:

  • An open-label study involving 34 patients with refractory migraine headaches.
  • Zonisamide dosage initiated at 100 mg/day, titrated up to 400 mg/day as tolerated.
  • Assessment of headache parameters at baseline and at 1, 2, and 3 months post-initiation.

Related Experiment Videos

Main Results:

  • Statistically significant improvements in headache severity (P <0.01), duration (P <0.05), and frequency (P <0.05) were observed after one month and sustained through three months.
  • Zonisamide was generally well tolerated, with only 11.8% of patients discontinuing due to adverse events.
  • Reported adverse events, including dysphoria and difficulty concentrating, were transient and manageable.

Conclusions:

  • Zonisamide demonstrates potential as a safe and effective adjunctive therapy for migraine prevention.
  • The findings suggest zonisamide may offer a new therapeutic option for individuals with difficult-to-treat migraines.
  • Further confirmation through double-blind, placebo-controlled studies is recommended to validate these promising results.